Clinical trials: Neoplasms Recurrence
Gynecological Malignancies
A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies
This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with recurrent or metastatic gynecologic malignancies.
- Trial name
- NCT06131450
- Testing
- BL-M07D1
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Relapsed or Refractory Multiple Myeloma
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and…
- Trial name
- NCT07018050
- Testing
- QLS32015, Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Bladder Neoplasms
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in…
- Trial name
- NCT00406068
- Testing
- Mycobacterial cell wall-DNA complex
- Where
- 31 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Bioniche Life Sciences Inc.
Head Neck Cancer, Intratumoral Injection
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
- Trial name
- NCT05838729
- Testing
- RiMO-301
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Locally Advanced Solid Tumors, Recurrent Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802…
- Conditions
- Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT06031441
- Testing
- RO7566802, Atezolizumab
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Glioblastoma Multiforme
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801.
- Trial name
- NCT05222802
- Testing
- ERAS-801
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Katmai Pharmaceuticals Inc.
Recurrent/Metastatic Breast Cancer
Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects
TQB3616 capsule is a small molecule oral drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., which inhibits cyclin-dependent kinases 4 and 6 (CDK4/6).
- Trial name
- NCT05344729
- Testing
- TQB3616 Capsule
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatic Carcinoma
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.
- Trial name
- NCT01770431
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Genmab
Recurrent Ovarian Cancer
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent ovarian cancer.
- Trial name
- NCT04718740
- Testing
- fluzoparib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
HER2 + Breast Cancer
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
- Trial name
- NCT07294508
- Testing
- HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory…
- Trial name
- SUCCESSOR-1 (NCT05519085)
- Testing
- mezigdomide, Pomalidomide, Bortezomib
- Where
- 266 sites in United States, Argentina and 27 more
- Volunteers
- 810 people
- Sponsor
- Celgene
Hormone-refractory Prostate Cancer
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment.
- Trial name
- NCT05997615
- Testing
- VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel
- Where
- 26 sites in United States, Australia and 2 more
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Multiple Myeloma
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell…
- Trial name
- PANORAMA-1 (NCT01023308)
- Testing
- Panobinostat, Bortezomib, Dexamethasone
- Where
- 210 sites in United States, Argentina and 32 more
- Volunteers
- 767 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Non-Hodgkin
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults.
- Trial name
- NCT07607925
- Testing
- GSK5926371
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Head and Neck Squamous Cell Carcinomas, Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This Phase II study is a clinical trial exploring the efficacy and safety of BL-M08D1 for injection in patients with recurrent or metastatic squamous cell carcinoma of the head and neck and other solid tumors.
- Trial name
- NCT07788950
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.